News
French Registration of Insect Repellent Product TyraTech Naturals®
Field Trials Demonstrate Superior Performance Over Current Market-Leading Products
11 April 2013
TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has been granted registration for its new personal insect repellent in France. This means that the product is approved and ready for immediate commercialisation in retail channels. The personal insect repellent features TyraTech's Nature's Technology™ platform which harnesses the power of natural ingredients to deliver best-in-class efficacy and family safety.
Both Laboratory and Field trials have demonstrated that the personal insect repellent significantly outperforms 15% DEET for both mosquito and tick repellency (DEET being the most common active ingredient in insect repellents). Trials have been carried out using various species of mosquito including those which are known vectors of West Nile Virus, Malaria, Dengue fever, yellow fever and St Louis encephalitis. Tick trials have included species which are vectors for Lyme disease, Rocky Mountain spotted fever and Southern tick associated rash infection (STARI).
The Company has filed for patent protection for its personal insect repellent formulation and has submitted data from the laboratory and field trials for publication in two international journals. The Company has already been granted registrations for its personal insect repellent in the U.S., German and UK markets.
Bruno Jactel, Chief Executive of TyraTech, commented: "TyraTech's personal insect repellent provides an effective and timely solution for families seeking superior protection without concerns over safety. Our portfolio of European registrations is expected to continue to grow in the coming months. We are currently in the process of evaluating commercial and retail partners for this product and our other products."
Further information on TyraTech's personal insect repellent is available on the Company's website at www.tyratech.com/RepellentTechnologyOverview
For further information please contact:
| TyraTech Inc. Alan Reade, Executive Chairman Bruno Jactel, Chief Executive Officer |
Tel: +1 919 415 4310 Tel: +1 919 415 4340 |
| N+1 Singer, Nominated Adviser and Joint Broker Aubrey Powell / Alex Wright |
Tel: +44 20 7496 3000 |
| First Columbus LLP, Joint Broker Chris Crawford |
Tel: +44 20 3002 2070 |
| Walbrook, Financial PR and IR Bob Huxford / Paul Cornelius |
Tel: +44 20 7933 8792 |
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.